Volpara (ASX:VHT) share price edges lower despite biggest contract win

It seems the medical imaging company's shares are being dragged lower by broader market weakness.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is heading south today regardless of the company's significant positive announcement.

At the time of writing, the healthcare technology company's shares are down 2.54% to $1.15.

a sonographer monitors an image of a patient's breast on a screen with the patient standing at an imaging device in the background.

Image source: Getty Images

Volpara secures largest-ever contract

According to the company's announcement, Volpara advised it has signed its biggest contract to date with a leading US outpatient diagnostic imaging provider.

The five-year deal is valued at US$2.15 million which represents an annual recurring revenue (ARR) of US$430,000.

Under the agreement, Volpara will install its Patient Hub software across the customer's network of imaging centres. The software solution is expected to provide a standardised patient tracking platform that incorporates Volpara Risk and Scorecard.

As such, this will enable the customer to accurately decide the appropriate personalised breast cancer screening pathway for each patient.

Volpara estimates that at least one of its software products is used in the breast cancer screening of more than 33% of women in the US.

Whilst the announcement is extremely positive, it appears the broader All Ordinaries Index (ASX: XAO) is weighing down the Volpara share price. The index is currently down 0.90% to 7,508.7 points.

Volpara group CEO Dr Ralph Highnam commented:

While we would not normally announce individual deals, this is Volpara's highest-value contract signed to date.

We are experiencing tremendous momentum for our platform in the market as we bring together best-of-breed patient tracking, risk assessment, and density scoring to allow our customers to provide their patients with the individualised care they deserve.

Our platform provides both Volpara and our customers with a significant advantage and is enabling us to seek out opportunities that did not exist even a couple of years ago.

About the Volpara share price

The past 12 months have been disappointing for investors with the company's shares down 13%. Year-to-date, their losses are further magnified, almost 20% lower over the period.

Based on today's price, Volpara presides a market capitalisation of roughly $29 million and has approximately 251.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »